Low-molecular-weight heparin for initial treatment of venous thromboembolism

American Family Physician

Volumn 72, Issue 1, 2005, Pages 75-76

  Brewer, Dan ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

AGED; CASE REPORT; DRUG INDICATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; SHORT SURVEY; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; AGED; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DRUG COSTS; EVIDENCE-BASED MEDICINE; FEMALE; FEMORAL VEIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAFETY; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 21844456866     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (4)

1. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004;(4):CD001100.
2. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004;140:175-83.
3. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-7.
4. van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis-an economic evaluation. TASMAN Study Group. Thromb Haemost 1998;79:259-63.